Michael J. Koren

Apr 8, 2024 | jamanetwork.com | Steven Nissen |Kathy E. Wolski |Gerald Watts |Michael J. Koren

Key PointsQuestion  What is the safety and tolerability of zerlasiran and its effect on lipoprotein(a) serum concentrations? Findings  The trial enrolled 32 healthy participants and 36 patients with cardiovascular disease and lipoprotein(a) concentrations 150 nmol/L or greater. No serious adverse event occurred. The median change from baseline in lipoprotein(a) concentration 365 days after single doses for placebo, 300 mg, and 600 mg were 14%, −30%, and −29%.

Dec 27, 2023 | podcasts.apple.com | Michael J. Koren

Are myths about vaccines and their DNA-altering capabilities clouding your judgement? Let us arm you with facts as we journey through the complexities of viruses and the marvels of modern immunizations. Together, we’ll navigate the intricate relationship between these microscopic invaders and the defense mechanisms of our bodies.

Jun 14, 2023 | podcasts.apple.com | Michael J. Koren

Ever wondered why atrial fibrillation (AFib) is considered the most widespread heart rhythm problem in the world? Join us for an eye-opening conversation with Dr. Neil Sanghvi, an electrophysiologist, as we uncover the prevalence, causes, and symptoms of AFib, which currently affects 5-7 million Americans and is projected to impact 15 million people in the next 20 years.